We’re excited to announce our Malta expansion is complete!
We will be returning to our 658 Malta location beginning Monday, August 27, 2018.
- Posted on: Jul 24 2018
We will be returning to our 658 Malta location beginning Monday, August 27, 2018.
The FDA has expanded the indication for Omidria, a mydriatic and NSAID combination agent, to include use in pediatric patients from birth through 17 years. Source: AAO
Findings from this retrospective study suggest that patients with initial suboptimal response to an intravitreal corticosteroid implant may continue to have a suboptimal response on long-term follow-up. Source: AAO
This study reviews the bacterial origins and potential causative factors of preseptal cellulitis and abscesses involving the eyebrow. Source: AAO
This week researchers unveil a temperature-sensitive sealant that could buy time for open-globe injuries, and an omega-3-supplemented eye drop gets approved in Europe. Source: AAO
Physicians may soon have a steroid alternative in their uveitis treatment toolkit: A phase 2 trial finds that the new aldehyde trap drug reproxalap (Aldeyra Therapeutics) is noninferior to prednisolone acetate (Pred Forte) at reducing ocular inflammation in patients with noninfectious anterior uveitis. Source: AAO
A new Zika vaccine shows promising safety and immunogenicity, according to a phase 1 trial by the Vaccine Research Center at the NIH. Source: AAO
Investigators prospectively compared the safety profiles of 2 IOL implantation techniques in children younger than 4 years old. Source: AAO
This prospective pilot study assessed the efficacy of venous sinus stenting in patients with idiopathic intracranial hypertension (IIH). Source: AAO
This prospective case series compares the efficacy of a computer-assisted system versus manual marking for toric IOL alignment. Source: AAO
Tel: 518-580-0553
Get Directions »
Tel: 518-580-0553
Get Directions »
Tel: +1 (518) 580-0553
Get Directions »